Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > ORGANIZATION
ORGANIZATION
- Economic Burden of Preventable Cancer “Over 1 Trillion Yen”: NCC, NCGM
August 17, 2023
- INES Proposes Extension of Public Funding for COVID Drugs
August 7, 2023
- IRA Could Create New Type of Drug Loss, Affecting Japan Too: PhRMA Official
July 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- JPA to Issue Policy Proposal to Address Lingering Supply Crisis
July 24, 2023
- More People Seek Self-Medication Tax Break in 2022
July 24, 2023
- JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
July 21, 2023
- Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
- Policy Veterans’ Group Lauds Expert Panel’s Report as “Epoch Making”
July 20, 2023
- Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
July 19, 2023
- Reform Regenerative Medicine Systems to Fight Lag, Loss: FIRM to Japan Govt
July 12, 2023
- Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
- PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
July 4, 2023
- Generic Use Rate at 80.7% in FY2022: JGA
June 30, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- FPMAJ Chief Shows Enthusiasm toward Drug Pricing Reform, Vows to Exchange Views with All Affiliate Groups
June 26, 2023
- New JPMA Director General Keen to Make “Special Price Maintenance” Happen after 15 Years
June 23, 2023
- FPMAJ Makes 1st Update for Generic Supply Guidelines in 9 Years
June 22, 2023
- Patient Group Requests Early Approval of New ALS Drugs in Japan
June 22, 2023
- Astellas’ Yoshitsugu Shitaka Elected as New FIRM Chair
June 20, 2023
ページ
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…